In WP1 we aim to develop new tumour-targeted drugs to selectively block key innate and adaptive immune checkpoints in the tumour micro-environment. Specifically, various negative regulators of innate immunity, such as PD-1, TIM-3 and CD47, have been described and various newly identified checkpoints are emerging.
In WP2 we aim to develop new tumour-targeted antibodies and antibody fusion proteins to selectively activate key co-stimulatory receptors of the TNFRSF in the tumour micro-environment. Herewith, local optimal co-stimulation of T-cell is provided to ensure induction and execution of anticancer immune response in the absence of systemic immune-related side-effects.
In WP3, we aim to achieve our training Objective to deliver researchers with interdisciplinary and intersectoral expertise. Hereto, I-DireCT provides a versatile training programme that addresses academic and industrial expertise and personal skills. The training programme encompasses: (1) original research projects as the core of doctoral education, performed at the host institution and through secondments; (2) formal training via courses and workshops by each institution; (3) original training components offered by the consortium network; and (4) components accessed by ESRs through existing outside-network activities.
The overall objective of WP4 is to ensure coherent external communication of I-DireCT activities, progress and achievements and the optimal management and exploitation of research outcomes and resulting Intellectual Property (IP). Objectives are to 1. create visibility and encourage project outreach; 2. coordinate dissemination, knowledge, and innovation activities in a specific dissemination strategy; 3. foster innovation and exploitation of results.
The objectives of WP5 are to manage and coordinate the I-DireCT consortium by:
The objective is to ensure compliance with the 'ethics requirements' set out in this work package.